Full text is available at the source.
Abstract
Antidiabetic therapy combining a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide-1 receptor agonist (GLP-1RA) is evaluated for its effects on liver histology in adults with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes.
- Type 2 diabetes is linked to the worsening of metabolic dysfunction-associated steatohepatitis (MASH).
- The study focuses on adults who have been confirmed to have MASH through biopsy.
- Adding an SGLT2 inhibitor to GLP-1RA therapy may have a beneficial impact on liver tissue health.
Simplified